Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PrimeC in ALS
NCT04165850Phase 2Completed
- Sponsor
- NeuroSense Therapeutics
- Start
- Nov 2019
- Primary completion
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of PrimeC in amyotrophic lateral sclerosis (ALS), sponsored by NeuroSense Therapeutics. Started Nov 2019; status: completed.
02
Drugs
PrimeC
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT04165850.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04165850.